Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Maria Sofia Semprini

1PUBLICATIONS

13CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Dec 05, 2024

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring <i>BRAF</i> Class 3 Mutations.

Alessandro Di Federico, Stefania Angelicola, Mariateresa Frascino

Pageof 1

Frequent Collaborators

1 joint publications

Alessandro Di Federico

1 joint publications

Stefania Angelicola

1 joint publications

Francesca Ruzzi

1 joint publications

Hugo De Jonge

1 joint publications

Andrea De Giglio

1 joint publications

Francesca Sperandi

1 joint publications

Stefano Brocchi

1 joint publications

Francesca Giunchi

1 joint publications

Elisa Gruppioni

1 joint publications

Annalisa Altimari

Frequent Collaborators

1 joint publications

Alessandro Di Federico

1 joint publications

Stefania Angelicola

1 joint publications

Francesca Ruzzi

1 joint publications

Hugo De Jonge

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos